Top Qs
Timeline
Chat
Perspective

Sirukumab

Monoclonal antibody From Wikipedia, the free encyclopedia

Remove ads

Sirukumab (INN, USAN) (developmental code name CNTO-136, tentative brand name Plivensia) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).[2]

Quick Facts Monoclonal antibody, Type ...

Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor.[3]

Remove ads

Clinical trials

Rheumatoid arthritis

It has started clinical trials.[4] and reported some phase II results.[3]

In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[5] By Feb 2017 SIRROUND-D was considered to have met both co-primary endpoints.[6]

Research

The drug was previously under development for the treatment of depression.[7]

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads